請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8796
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 謝豐舟,張金堅 | |
dc.contributor.author | Sou-Tyau Chiu | en |
dc.contributor.author | 邱守苕 | zh_TW |
dc.date.accessioned | 2021-05-20T20:01:28Z | - |
dc.date.available | 2009-12-22 | |
dc.date.available | 2021-05-20T20:01:28Z | - |
dc.date.copyright | 2009-12-22 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-11-16 | |
dc.identifier.citation | Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers. Ann Oncol. 2007 Mar;18(3):485-90.
Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espín E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S Jr, Arango D. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res. 2005 Nov 15;65(22): 10170-3. Asadi FK, Sharifi R. Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines. Int Urol Nephrol. 1995;27(1):67-80. Barrios A, Poole RJ, Durbin L, Brennan C, Holder N, Wilson SW. Eph/Ephrin signaling regulates the mesenchymal-to-epithelial transition of the paraxial meso- derm during somite morphogenesis. Curr Biol. 2003 Sep 16;13(18):1571-82. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, Clevers H. Beta- catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell. 2002 Oct 18;111(2):251-63. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H. EphB receptor activity suppresses colorectal cancer progression. Nature. 2005 Jun 23;435(7045): 1126-30. Biamonti G, Ruggiu M, Saccone S, Della Valle G, Riva S. Two homologous genes, originated by duplication, encode the human hnRNP proteins A2 and A1. Nucleic Acids Res. 1994 Jun 11;22(11):1996-2002. Böhme B, Holtrich U, Wolf G, Luzius H, Grzeschik KH, Strebhardt K, Rübsamen-Waigmann H. PCR mediated detection of a new human receptor- tyrosine-kinase, HEK 2. Oncogene. 1993 Oct;8(10):2857-62. Booth C, Brady G, Potten CS. Crowd control in the crypt. Nat Med. 2002 Dec;8(12): 1360-1. Boyer B, Vallés AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol. 2000 Oct 15;60(8):1091-9. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 2005;179(1-2):56-65. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 2002 May 15;62(10):2840-7. Chen J, Zhuang G, Frieden L, Debinski W. Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res. 2008 Dec 15;68(24):10031-3. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85. Chiu ST, Hsieh FJ, Chen SW, Chen CL, Shu HF, Li H. Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):437-43. Chu FF, Doroshow JH, Esworthy RS. Expression, characterization, and tissue dis- tribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI. J Biol Chem. 1993 Feb 5;268(4):2571-6. Chu FF, Esworthy RS, Ho YS, Bermeister M, Swiderek K, Elliott RW. Expression and chromosomal mapping of mouse Gpx2 gene encoding the gastrointestinal form of glutathione peroxidase, GPX-GI. Biomed Environ Sci. 1997 Sep;10(2-3):156-62. Clevers H, Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res. 2006 Jan 1;66(1):2-5. Clevers,H. Wnt/β-catenin signaling in development and disease. Cell. 2006 Nov 3;127 (3):469-80. Cortina C, Palomo-Ponce S, Iglesias M, Fernández-Masip JL, Vivancos A, Whissell G, Humà M, Peiró N, Gallego L, Jonkheer S, Davy A, Lloreta J, Sancho E, Batlle E. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet. 2007 Nov;39(11):1376- 83. Cuenca RE, Azizkhan RG, Haskill S. Characterization of GRO α, β and γ expression in human colonic tumours: potential significance of cytokine involvement. Surg Oncol. 1992 Aug;1(4):323-9. Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz S Jr, Arango D. EPHB4 and survival of colorectal cancer patients. Cancer Res. 2006 Sep 15;66 (18):8943-8. Ellenbroek SI, Collard JG. Rho GTPases: functions and association with cancer. Clin Exp Metastasis. 2007;24(8):657-72. Fuchs SY, Ougolkov AV, Spiegelman VS, Minamoto T. Oncogenic β-catenin signaling networks in colorectal cancer. Cell Cycle. 2005 Nov;4(11):1522-39. Fukata M, Kaibuchi K. Rho-family GTPases in cadherin-mediated cell-cell ad- hesion. Nat Rev Mol Cell Biol. 2001 Dec;2(12):887-97. Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, Yancopoulos GD. Ephrin-B2 selectively marks arterial vessels and neovasculari- zation sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol. 2001 Feb 15;230(2):151-60. Golby SJ, Chinyama C, Spencer J. Proliferation of T-cell subsets that contact tumour cells in colorectal cancer. Clin Exp Immunol. 2002 Jan;127(1):85-91. Grad JM, Dai JL, Wu S, Burnstein KL. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol. 1999 Nov;13(11):1896-911. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007 Jun;39(3):305-18. Guo DL, Zhang J, Yuen ST, Tsui WY, Chan AS, Ho C, Ji J, Leung SY, Chen X. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis. 2006 Mar;27(3):454-64. Holmberg J, Genander M, Halford MM, Annerén C, Sondell M, Chumley MJ, Silvany RE, Henkemeyer M, Frisén J. EphB receptors coordinate migration and prolifera- tion in the intestinal stem cell niche. Cell. 2006 Jun 16;125(6):1151-63. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 2007 Nov;213(2):374-83. Hood L, Kronenberg M, Hunkapiller T. T cell antigen receptors and the immuno- globulin supergene family. Cell. 1985 Feb;40(2):225-9. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005 Oct;17(5):548-58. Iden S, Collard JG. Crosstalk between small GTPases and polarity proteins in cell polarization. Nat Rev Mol Cell Biol. 2008 Nov;9(11):846-59. Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N. Expression profiling of epithelial plasticity in tumor progression. Oncogene. 2003 Oct 16;22(46):7155-69. Jubb AM, Zhong F, Bheddah S, Grabsch HI, Frantz GD, Mueller W, Kavi V, Quirke P, Polakis P, Koeppen H. EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res. 2005 Jul 15;11(14):5181-7. Kiemer AK, Takeuchi K, Quinlan MP. Identification of genes involved in epi- thelial-mesenchymal transition and tumor progression. Oncogene. 2001 Oct 11;20 (46): 6679-88. Konstantinova I, Nikolova G, Ohara-Imaizumi M, Meda P, Kucera T, Zarbalis K, Wurst W, Nagamatsu S, Lammert E. EphA-Ephrin-A-mediated beta cell com- munication regulates insulin secretion from pancreatic islets. Cell. 2007 Apr 20;129 (2):359-70. Kozii R, Wilson J, Persichetti J, Phelps V, Ball SE, Ball ED. Thy-1 expression on blast cells from adult patients with acute myeloid leukemia. Leuk Res. 1997 May; 21(5):381-5. Kruzelock RP, Short W. Colorectal cancer therapeutics and the challenges of applied pharmacogenomics. Curr Probl Cancer. 2007 Sep-Oct;31(5):315-66. Kumar R, Eastwood AL, Brown ML, Laurie GW. Human genome search in celiac disease: mutated gliadin T-cell-like epitope in two human proteins promotes T-cell activation. J Mol Biol. 2002 Jun 7;319(3):593-602. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006 Jul;169(1):279-93. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides sur- vival signals and predicts poor outcome. Br J Cancer. 2007 Apr 10;96(7):1083-91. Lamorte L, Royal I, Naujokas M, Park M. Crk adapter proteins promote an epi- thelial-mesenchymal-like transition and are required for HGF-mediated cell spread- ing and breakdown of epithelial adherens junctions. Mol Biol Cell. 2002 May;13(5): 1449- 61. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transi- tion: new insights in signaling, development, and disease. J Cell Biol. 2006 Mar 27;172 (7):973-81. Li BD, Budnick RM, Russo CA, Anderson GR, Stewart CC. Quantifying c-myc expression in c-myc antisense phosphorothioate oligodeoxynucleotide-treated leu- kemic and colon cancer cell lines. J Surg Res. 1995 Oct;59(4):485-92. Linghu H, Tsuda M, Makino Y, Sakai M, Watanabe T, Ichihara S, Sawa H, Nagashima K, Mochizuki N, Tanaka S. Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS. Oncogene. 2006 Jun 15;25(25):3547 -56. Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, Ellis LM. Co- expression of ephrin-Bs and their receptors in colon carcinoma. Cancer. 2002 Feb 15;94 (4):934-9. Liu X, Hawkes E, Ishimaru T, Tran T, Sretavan DW. EphB3: an endogenous mediator of adult axonal plasticity and regrowth after CNS injury. J Neurosci. 2006 Mar 22; 26(12):3087-101. Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L. EphB2 ex- pression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res. 2005 Sep 15;11(18):6450- 8. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell. 2005 Aug;8(2):111-8. Marquardt T, Shirasaki R, Ghosh S, Andrews SE, Carter N, Hunter T, Pfaff SL. Coexpressed EphA receptors and ephrin-A ligands mediate opposing actions on growth cone navigation from distinct membrane domains. Cell. 2005 Apr 8;121 (1):127-39. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005 Dec 1;19(23):2783-810. Mayer BJ, Hamaguchi M, Hanafusa H. A novel viral oncogene with structural similarity to phospholipase C. Nature. 1988 Mar 17;332(6161):272-5. Miao H, Strebhardt K, Pasquale EB, Shen TL, Guan JL, Wang B. Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem. 2005 Jan 14;280(2):923-32. Michael WM, Choi M, Dreyfuss G. A nuclear export signal in hnRNP A1: a signal- mediated, temperature-dependent nuclear protein export pathway. Cell. 1995 Nov 3;83(3):415-22. Moustakas A, Heldin C-H. Non-Smad TGF-β signals. J Cell Sci. 2005 Aug 15;118 (Pt 16):3573-84. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transi- tions during embryogenesis and cancer progression. Cancer Sci. 2007 Oct; 98(10): 1512-20. Miura K, Nam JM, Kojima C, Mochizuki N, Sabe H. EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts. Mol Biol Cell. 2009 Apr;20 (7):1949-59. Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech. 2002 Oct 1;59(1):58-67. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 2006 Aug;8 (8):815-25. Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res. 2007 May 1; 67(9):3994-7. Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesen- chymal transition during tumor development. Clin Exp Metastasis. 2008;25(6):593- 600. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75. Petersen BE, Goff JP, Greenberger JS, Michalopoulos GK. Hepatic oval cells ex- press the hematopoietic stem cell marker Thy-1 in the rat. Hepatology. 1998 Feb;27 (2):433-45. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998 Mar 12;392(6672):190- 3. Quarmby VE, Beckman WC Jr, Wilson EM, French FS. Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol Endocrinol. 1987 Dec;1(12):865-74. Rajeevan MS, Vernon SD, Taysavang N, Unger ER. Validation of arraybased gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagn. 2001 Feb;3 (1):26- 31. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005 Apr 14;434 (7035):843-50. Ridley,A.J. (2001) Rho GTPases and cell migration. J Cell Sci. 2001 Aug;114(Pt 15): 2713-22. Rodrigues SP, Fathers KE, Chan G, Zuo D, Halwani F, Meterissian S, Park M. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol Cancer Res. 2005 Apr;3(4):183-94. Silva IS, Morsch DM, Urnauer L, Spritzer PM. Androgen-induced cell growth and c-myc expression in human non-transformed epithelial prostatic cells in primary culture. Endocr Res. 2001 Feb-May;27(1-2):153-69. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33. Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, Daniel TO. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 1998 Mar 1;12(5):667-78. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol. 2001 Dec 21;2:15. Stokowski A, Shi S, Sun T, Bartold PM, Koblar SA, Gronthos S. EphB/ephrin-B interaction mediates adult stem cell attachment, spreading, and migration: implica- tions for dental tissue repair. Stem Cells. 2007 Jan;25(1):156-64. Takino T, Nakada M, Miyamori H, Yamashita J, Yamada KM, Sato H. CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res. 2003 May 1;63(9):2335-7. Tang XX, Brodeur GM, Campling BG, Ikegaki N. Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin Cancer Res. 1999 Feb;5(2):455-60. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002 Jun;2(6):442-54. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H. The beta- catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002 Oct 18;111(2):241-50. Wang JY. Eph tumour suppression: the dark side of Gleevec. Nat Cell Biol. 2006 Aug; 8(8):785-6. Willson CA, Miranda JD, Foster RD, Onifer SM, Whittemore SR. Transection of the adult rat spinal cord upregulates EphB3 receptor and ligand expression. Cell Transplant. Cell Transplant. 2003;12(3):279-90. Willson CA, Foster RD, Onifer SM, Whittemore SR, Miranda JD. EphB3 receptor and ligand expression in the adult rat brain. J Mol Histol. 2006 Nov;37 (8-9):369- 80. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL. Prognostic and diagnostic signific- ance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2004 Feb 15;10(4):1401-8. Wu Q, Lind GE, Aasheim HC, Micci F, Silins I, Tropé CG, Nesland JM, Lothe RA, Suo Z. The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers. Epigenetics. 2007 Oct-Dec;2(4):237-43. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 1;65(11):4623-32. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS. Up-regulation of EphB4 in mesothelioma and its biologic- al significance. Clin Cancer Res. 2005 Jun 15;11(12):4305-15. Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, Smith DL, Buscarini M, Broek D, Quinn DI, Weaver FA, Gill PS. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006 Feb 2;25(5):769-80. Xu LH, Yang X, Bradham CA, Brenner DA, Baldwin AS Jr, Craven RJ, Cance WG. The focal adhesion kinase suppresses transformation-associated, anchorage- in-dependent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem. 2000 Sep 29;275(39):30597-604. Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R. The signi- ficance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2008 Sep;134(9): 985-91. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001 March 1;61 (5):2301-3. Zou TT, Selaru FM, Xu Y, Shustova V, Yin J, Mori Y, Shibata D, Sato F, Wang S, Olaru A, Deacu E, Liu TC, Abraham JM, Meltzer SJ. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene. 2002 Jul 18;21(31):4855-62. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8796 | - |
dc.description.abstract | 在已開發國家,大腸直腸癌是造成癌症死亡的主因之一。近年來,某些標靶治療藥物已被證實能夠以有效率且少副作用的方式來治療外科手術無法切除的癌細胞,而瞭解癌症分子訊息傳遞路徑乃是發展和臨床應用標靶治療的先決條件。本研究有兩個部分。第一部分乃分子流行病學之研究,目地在尋找及確認人類大腸直腸癌中和臨床病理因子相關的向上調控基因。第二部分則專注於EphB3基因功能的剖析。已知EphB3是一種細胞膜上的酪氨酸磷酸激脢受體,在消化道中只有小腸絨毛隱窩以及大腸黏膜隱窩底部的始祖細胞(幹細胞)會表現EphB3。此外,EphB3也被證實是一個腫瘤抑制基因。這兩項引人注意的特點使我們決定要進一步探索EphB3的生物學功能。我們的研究不但揭露了EphB3在腸道和癌症生物學的一個嶄新的角色 (EphB3/ephrin-B分子訊息能夠促進細胞的極化以及上皮化,也就是所謂的間質上皮轉換),同時也顯示活化此一分子訊息極有潛力成為標靶治療的新標地。
在研究的第一部分,我們利用四位病人的四組樣本進行cDNA微陣列實驗。在這四個DNA晶片上都呈現向上調控的基因共有29個。我們挑選其中20個基因進行晶片實驗後之二次確認。確認的方法是定量RT-PCR實驗,樣本共有31組,取自於原來4位病人以及另外27位病人的外科檢體。20個基因中只有8個基因通過定量RT-PCR實驗的再確認。我們發現,經確認為向上調控的基因在31組樣本中,各有數組樣本沒有呈現向上調控,而這些樣本的腫瘤行為以及臨床病理特徵也不同於該基因呈現向上調控的其他腫瘤樣本。我們將8個基因在31組樣本中有或沒有呈現向上調控和31組樣本各自的10項臨床病理因子合或不合於於某條件,利用卡方檢定或是費雪氏精密檢定進行統計學的相關分析。結果發現其中6個基因的向上調控與否可以對應到是否出現某特定腫瘤行為或是臨床特徵: THY1以及 PHLAD1的向上調控和大腸直腸癌病人出現貧血狀態有統計相關 (P = 0.036 以及 P = 0.009);HNRPA1的向上調控和位於右側的大腸癌有統計相關 (P = 0.027);GPX2的向上調控和大腸直腸癌腫瘤細胞分化程度較高有統計相關 (P = 0.019);c-MYC的向上調控和男性大腸直腸癌腫瘤有統計相關 (P = 0.012);GRO1的向上調控和病人年齡小於65歲的大腸直腸癌有統計相關 (P = 0.010);此外,GRO1的基因表現愈強,大腸直腸腫瘤的侵襲性及惡性程度有愈低的傾向 (傾向乃指0.05 < P < 0.1)-即血中CEA level愈低、淋巴轉移愈少、Dukes’ stage愈早期 (P值分別為P = 0.058、P = 0.060、P = 0.075)。最後,我們也將20個基因在31組樣本中的mRNA levels利用統計學的廻歸分析兩兩互相進行統計檢定,期望找出20個基因之間那些基因在基因表現上相關。結果發現,HNPRA1和 c-MYC這兩個基因的基因轉錄強弱存在非常緊密的統計相關 (相關係數r = 0.948 )。本研究第一部分的結論如下:(1) 利用另外一種獨立的實驗方法來驗證DNA微陣列實驗的結果是必要的。(2) 利用統計學的相關分析可以找到和腫瘤生物行為以及臨床病理因子相對應的基因。 2005年Batlle等人提出基因剔除小鼠的活體證據證明Ephb3是腫瘤抑制基因。同一組研究學者於兩年後又提出證據證明EphB是藉由一種新的機轉-EphB媒介之腫瘤隔離作用 (EphB-mediated tumor compartmentalization) 來達到抑制腫瘤生長的效果。然而,是否還有其他因素能夠促成EphB媒介之腫瘤抑制作用則尚未有人報導。另一方面,Eph家族中的EphA4/ephrin-A以及EphB4/ephrin-B2分子訊息已經被證實能夠促進間質上皮轉換。因此,我們假設EphB3/ephrin-B分子訊息也會有類似的作用,並且臆測此一作用能夠抑制腫瘤生長。在研究的第二部分,我們首先檢視大腸直腸癌病人腫瘤樣本中EphB3的表現狀態。我們發現EphB3基因的表現在整體上是大腸直腸癌腫瘤高於正常大腸黏膜組織,但是如果將36組樣本依照腫瘤惡性程度分成Dukes’ stages B,C和D三組,就會發現:早期未擴散的大腸直腸癌 (即Dukes’ B) 腫瘤組織有很高的EphB3基因表現,而局部擴散的大腸直腸癌腫瘤 (Dukes’ C) 以及遠處轉移的大腸直腸癌腫瘤(Dukes’ D) 的EphB3基因表現都非常的微弱;這暗示EphB3在大腸直腸癌中扮演腫瘤抑制基因的角色;此部分的臨床證據呼應了Batlle等人在Ephb3-/- ; ApcMin/+基因剔除小鼠的實驗結果。接下來,我們將EphB3的表現質體轉染原本不會表現EphB3的HT-29人類大腸癌細胞株,並篩選出能夠持續表現EphB3的穩定細胞株。穩定細胞株可以同時表現EphB3 receptor以及其ligands (wildtype HT-29細胞本身即會表現ephrin-B1及ephrin-B2這兩種EphB3的ligands),所以EphB3/ephrin-B分子訊息在這些穩定細胞株是屬於同位交互作用 (interaction in cis)。分析這些穩定細胞株可以獲得和間質上皮轉換有關的細胞分子生物學證據。我們發現:持續表現EphB3能夠抑制HT-29細胞在培養皿平盤中的生長、在洋菜凝膠之中的懸浮生長,以及在裸鼠身上異種移植的腫瘤生長,並且誘發形態學、細胞行為以及分子傳遞訊息三個層面的變化,而這些變化都符合間質上皮轉換的條件。更專一的描述如下:持續表現EphB3能夠重組細胞骨架,包括將細胞的形態由伸展狀的外形變成上皮細胞的鵝卵石狀、構築細胞膜下層狀的肌動蛋白骨架 (cortical-actin-cytoskeleton),以及極化細胞膜上的E-cadherin和ZO-1分子。持續表現EphB3也會誘發細胞功能的改變,包括降低細胞的爬行能力、增加細胞的凋亡,以及增加依賴鈣離子的細胞-細胞間黏合力;顯然的,這些功能上的改變皆有利於間質上皮轉換。持續表現EphB3還可以減少間質細胞的分子標記 (降低fibronectin 以及 nuclear β-catenin),增加上皮細胞的分子標記 (包括ZO-1,E-cadherin 以及 plakoglobin),並且將能夠促進上皮間質轉換的已知分子路徑Crk-Rac1 pathway去活化。最後,我們發現:持續表現EphB3可以透過Wnt分子路徑增加ZO-1的表現,進而幫助建構細胞之間的tight junction。已知細胞之間tight junction的形成步驟是間質上皮轉換的最後一個環節,此一步驟和adherens junction、desmosome以及cortical-actin-cytoskeleton的形成代表了細胞極化程式的執行完畢,是上皮細胞分化終點的一項指標。 值得注意的另外一個事實就是,這些促進間質上皮轉換的因子同時也扮演著抑制腫瘤生長的角色,而這種角色的重疊也就是間質上皮轉換參與腫瘤抑制作用的證據。本研究第二部分的結論如下:(1) EphB3/ephrin-B分子訊息藉由重建上皮細胞與細胞間的連接來促進間質上皮轉換,而此種間質上皮轉換的促進作用同時也促成了EphB3媒介的腫瘤抑制作用。 (2) 活化EphB3/ephrin-B分子路徑能夠抑制大腸直腸癌的生長,EphB3 receptor有潛力成為大腸直腸癌標靶治療的分子標地。 | zh_TW |
dc.description.abstract | Colorectal cancer is one of the leading causes of cancer death in developed countries. Recently, targeted therapy has raised hopes for treating unresectable cancers, including colorectal cancer, more effectively with fewer side effects. Understanding the details of signaling transduction is prerequisite for development and clinical application of targeted therapy. The first part of this study aimed to find individual up-regulated genes responsible for clinicopathological variations in human colorectal cancer. The second part of this study aimed to disclose EphB3 gene function. We provided evidence demonstrating that EphB3/ephrin-B signaling was able to promote apico-basal polarization and epithelialization (promote mesenchymal- to-epithelial transition) – a new role for EphB3 in the biology of the gut and cancer, and activation of such signaling has great potential for targeted therapy.
PART I. Clinical Correlates of Up-regulated Genes in Colorectal Cancer (A Forward or Classical Genetics Study) We hypothesize that changes in the transcription of up-regulated genes are biologically meaningful and may be linked to variations in tumor behavior and clinical features. Genes up-regulated concurrently in four microarray experiments were taken as candidate genes. Twenty candidate genes were verified using real-time RT-PCR in these 4 and another 27 pairs of samples. The presence or absence of up-regulation of these genes was correlated with ten clinicopathological variables from 31 patients. The mRNA transcript levels of these 20 candidate genes in the 31 paired samples were also correlated with each other to disclose any expression relationship. 40% (8/20) of candidate genes were verified by real-time RT-PCR to have a tumor/normal expression ratio > 2. Up-regulation of THY1 and PHLAD1 was associated with the presence of anemia in colon cancer patients (p=0.036 and 0.009). Up-regulation of HNRPA1 was more significant in cancer growing in the right sided colon than the left side (p=0.027). Up-regulated GPX2 was related to a higher degree of tumor differentiation (p=0.019). c-MYC was significantly over-expressed in specimens from male rather than female colon cancer patients (p=0.012). GRO1 was significantly up-regulated in patients younger than 65 years old (p=0.010) and was found to be frequently over-expressed when cancers were less invasive. In addition, we found normalized transcript levels of HNPRA1 were tightly associated with that of c-MYC (r=0.948). We conclude that validation of microarray data using another independent laboratory approach is mandatory and statistical correlation between gene expression status and patient’s clinical features may reveal individual genes relevant to tumor behavior and clinicopathological variations in human colorectal cancer. PART II. EphB3 Promotes MET and Suppresses Tumor Growth (A Reverse Genetics Study) Receptor tyrosine kinase EphB3 is expressed in cells in the bottom of intestinal crypts near stem cell niches. Loss of Ephb3 has recently been reported to produce invasive colorectal carcinoma in ApcMin/+ mice and EphB-mediated compartment- alization was demonstrated to be a mechanism suppressing colorectal cancer progress- ion; however, it is unknown whether other factors contribute to EphB-mediated tumor suppression. EphA4/ephrin-A and EphB4/ephrin-B2 signaling have been reported to promote mesenchymal-to-epithelial transition (MET). Here, we examine whether EphB3/ephrin-B interaction has a similar effect and investigate its role in tumor suppression. We found in a clinical cohort that EphB3 expression was significantly reduced in advanced Dukes’ stage tumor specimens, so we over-expressed EphB3 in HT-29 cells by stable transfection. EphB3 over-expression inhibited HT-29 growth in monolayer cultures, anchorage-independent growth in soft agar, and xenograft growth in nude mice and initiated morphological, behavioral and molecular changes consistent with MET. Specifically, EphB3 over-expression reorganized cytoskeleton (converting spreading cells to a cobble-like epithelial morphology, patterning cortical-actin- cytoskeleton and polarizing E-cadherin and ZO-1), induced functional changes favoring MET (decreased Transwell migration, increased apoptosis and Ca2+- dependent cell-cell adhesion), decreased mesenchymal markers (fibronectin and nuclear β-catenin), increased epithelial markers (ZO-1, E-cadherin and plakoglobin) and inactivated CrkL–Rac1, a known epithelial-to-mesenchymal transition (EMT) signaling pathway. Additionally, crosstalk from Wnt signaling potentiated the restora- tion of epithelial cell-polarity. Noteworthily, the same factors contributing to MET, owing to EphB3 signaling, also facilitated tumor suppression. We conclude that EphB3/ephrinB interaction promotes MET by re-establishing epithelial cell-cell junctions and such an MET-promoting effect contributes to EphB3- mediated tumor suppression. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:01:28Z (GMT). No. of bitstreams: 1 ntu-98-Q90421012-1.pdf: 4114230 bytes, checksum: 334e595ab9d32fd7c602dc28f8c77f4c (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 論文口試委員審定書 i
誌謝與感恩 ii 中文摘要 iv 英文摘要 viii 博士論文內容 第一章 緒論 P.1 1.1 研究背景 1.2 研究動機 1.3 研究的起始點 1.4 研究的兩個階段 1.5 研究的假說之一 1.6 研究策略 1.7 Eph酪氨酸磷酸激脢受體家族簡介 1.8 EphB3 protein的組織學分佈以及已知的生理功能 I. 消化道以外的組織 II. 消化道 1.9 研究的假說之二 1.10 Eph酪氨酸磷酸激脢受體參與間質上皮轉換的例子 1.11 上皮間質轉換以及間質上皮轉換的定義 1.12 上皮間質轉換的分子訊息傳遞路徑 1.13 E-cadherin是上皮間質轉換以及間質上皮轉換中的樞紐分子 1.14 Wnt-β-catenin signaling pathway 是大腸直腸癌中最重要的分子訊息傳遞路徑 1.15 上皮間質轉換在腫瘤生成所扮演的角色 1.16 Crk adaptor protein在上皮間質轉換以及致癌過程之中所扮演的角色 1.17 Rac1在上皮間質轉換以及致癌過程之中所扮演的角色 1.18 Eph磷酸激脢受體家族在癌變發生作用所扮演的角色 1.19 EphB2、EphB3以及EphB4的腫瘤抑制作用 第二章 研究方法與材料 P.25 2.1 病人與臨床樣本 2.2 由組織樣本分離total RNA 2.3 DNA微陣列實驗 2.4 定量RT-PCR實驗 2.5 細胞株和細胞培養 2.6 EphB3表現質體、細胞轉染、以及穩定細胞株的建立 2.7 細胞質細胞核分離,免疫沈澱法和西方墨點轉漬法 2.8 細胞免疫螢光染色以及雷射共軛焦顯微鏡實驗 2.9 細胞核內β-catenin/TCF活性的測定-報導基因表現分析實驗 2.10 RNA干擾實驗 2.11 Rac1活性試驗 2.12 Transwell爬行試驗 2.13 E-cadherin-依賴性 (鈣離子-依賴性) 之細胞-細胞間黏著力強度的測量 I. 細胞分離實驗 II. 細胞凝聚實驗 2.14 細胞株於試管培養環境以及活體環境中之生長分析 I. 培養皿培養下之生長分析 II. 活體環境中之生長分析 2.15 細胞懸浮生長分析 2.16 細胞株於試管培養環境以及活體環境中細胞凋亡之偵測 I. 培養皿培養環境下之細胞凋亡偵測 II. 活體環境中之細胞凋亡偵測 2.17 統計資料分析 第三章 結果 P.41 結果之第一部分 -- 大腸直腸癌基因表現和臨床病理因子相關性之研究 結果之第二部分 -- 正常大腸上皮組織和大腸直腸癌腫瘤組織中EphB3酪氨酸磷酸激脢受體mRNA及protein的表現以及其臨床意義之研究 結果之第三部分 -- EphB3/ephrin-B分子訊息促進間質上皮轉換的細胞分子生物學證據 結果之第四部分 -- EphB3/ephrin-B分子訊息抑制大腸直腸癌的生長 第四章 討論 P.63 第五章 展望 P.87 第六章 論文英文簡述 P.99 第七章 參考文獻 P.119 第八章 圖表 P.131 第九章 附錄 P.159 | |
dc.language.iso | zh-TW | |
dc.title | EphB3/ephrin-B分子訊息在人類大腸直腸癌之臨床和細胞分子生物學研究 | zh_TW |
dc.title | Clinical, Cellular and Molecular Study of EphB3/ephrin-B Signaling in Human Colorectal Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 蔡世峰,李心予,廖永豐 | |
dc.subject.keyword | 大腸直腸癌,向上調控基因,臨床病理因子,cDNA微陣列實驗,微陣列實驗結果之再確認,定量RT-PCR,EphB3,ephrin-B,間質上皮轉換,腫瘤抑制基因, | zh_TW |
dc.subject.keyword | colorectal cancer,up-regulated gene,clinicopathological factors,cDNA microarray,post-array validation,real-time RT-PCR,EphB3,ephrin-B,mesenchymal-to-epithelial transition,tumor suppressor gene, | en |
dc.relation.page | 159 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2009-11-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf | 4.02 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。